These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30277862)

  • 21. A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.
    Khanna D; Denton CP; Furst DE; Mayes MD; Matucci-Cerinic M; Smith V; de Vries D; Ford P; Bauer Y; Randall MJ; Ebrahimpoor M; Kupcsik L; Stiers PJ; Deberdt L; Prasad N; Lim S; Pujuguet P; Ahmed S
    Arthritis Rheumatol; 2023 Aug; 75(8):1434-1444. PubMed ID: 36787101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis.
    Klein AL; Imazio M; Brucato A; Cremer P; LeWinter M; Abbate A; Lin D; Martini A; Beutler A; Chang S; Fang F; Gervais A; Perrin R; Paolini JF
    Am Heart J; 2020 Oct; 228():81-90. PubMed ID: 32866928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.
    Sundy JS; Schumacher HR; Kivitz A; Weinstein SP; Wu R; King-Davis S; Evans RR
    J Rheumatol; 2014 Aug; 41(8):1703-11. PubMed ID: 25028379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.
    Goldbach-Mansky R; Shroff SD; Wilson M; Snyder C; Plehn S; Barham B; Pham TH; Pucino F; Wesley RA; Papadopoulos JH; Weinstein SP; Mellis SJ; Kastner DL
    Arthritis Rheum; 2008 Aug; 58(8):2432-42. PubMed ID: 18668591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.
    Wannarong T; Muangchan C
    Rheumatol Int; 2018 Dec; 38(12):2279-2288. PubMed ID: 30206672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.
    Gordon JK; Martyanov V; Magro C; Wildman HF; Wood TA; Huang WT; Crow MK; Whitfield ML; Spiera RF
    Arthritis Res Ther; 2015 Aug; 17(1):213. PubMed ID: 26283632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial.
    van den Hombergh WMT; Kersten BE; Knaapen-Hans HKA; Thurlings RM; van der Kraan PM; van den Hoogen FHJ; Fransen J; Vonk MC
    Trials; 2018 Aug; 19(1):449. PubMed ID: 30134971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction () for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial.
    Zhou J; Yang D; Zhou SH; Wang JP; Liu YS; Wang SL
    Chin J Integr Med; 2018 Mar; 24(3):185-192. PubMed ID: 28197938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
    Khanna D; Clements PJ; Furst DE; Korn JH; Ellman M; Rothfield N; Wigley FM; Moreland LW; Silver R; Kim YH; Steen VD; Firestein GS; Kavanaugh AF; Weisman M; Mayes MD; Collier D; Csuka ME; Simms R; Merkel PA; Medsger TA; Sanders ME; Maranian P; Seibold JR;
    Arthritis Rheum; 2009 Apr; 60(4):1102-11. PubMed ID: 19333948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.
    Lovell DJ; Giannini EH; Reiff AO; Kimura Y; Li S; Hashkes PJ; Wallace CA; Onel KB; Foell D; Wu R; Biedermann S; Hamilton JD; Radin AR
    Arthritis Rheum; 2013 Sep; 65(9):2486-96. PubMed ID: 23754188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
    Denton CP; Merkel PA; Furst DE; Khanna D; Emery P; Hsu VM; Silliman N; Streisand J; Powell J; Akesson A; Coppock J; Hoogen Fv; Herrick A; Mayes MD; Veale D; Haas J; Ledbetter S; Korn JH; Black CM; Seibold JR; ;
    Arthritis Rheum; 2007 Jan; 56(1):323-33. PubMed ID: 17195236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
    Klein AL; Imazio M; Cremer P; Brucato A; Abbate A; Fang F; Insalaco A; LeWinter M; Lewis BS; Lin D; Luis SA; Nicholls SJ; Pano A; Wheeler A; Paolini JF;
    N Engl J Med; 2021 Jan; 384(1):31-41. PubMed ID: 33200890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
    Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
    Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J
    Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
    Khanna D; Denton CP; Lin CJF; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE
    Ann Rheum Dis; 2018 Feb; 77(2):212-220. PubMed ID: 29066464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis.
    Khan K; Xu S; Nihtyanova S; Derrett-Smith E; Abraham D; Denton CP; Ong VH
    Ann Rheum Dis; 2012 Jul; 71(7):1235-42. PubMed ID: 22586157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.
    Hoffman HM; Throne ML; Amar NJ; Cartwright RC; Kivitz AJ; Soo Y; Weinstein SP
    Clin Ther; 2012 Oct; 34(10):2091-103. PubMed ID: 23031624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.
    Mitha E; Schumacher HR; Fouche L; Luo SF; Weinstein SP; Yancopoulos GD; Wang J; King-Davis S; Evans RR
    Rheumatology (Oxford); 2013 Jul; 52(7):1285-92. PubMed ID: 23485476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
    Spiera R; Kuwana M; Khanna D; Hummers L; Frech TM; Stevens W; Matucci-Cerinic M; Kafaja S; Distler O; Jun JB; Levy Y; Leszcyzński P; Gordon J; Steen V; Lee EB; Jankowski T; Litinsky I; Chung L; Hsu V; Mayes M; Sandorfi N; Simms RW; Finzel S; de Vries-Bouwstra J; Constantine S; Dgetluck N; Dinh Q; Bloom BJ; Furst DE; White B; Denton CP;
    Arthritis Rheumatol; 2023 Sep; 75(9):1608-1618. PubMed ID: 37098795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.